Pharma Industry Business Outlook and Procurement Report H1 - 2016 - Research and Markets....
Interesting H1 Report especially around the key findings.
After a number of meetings in the last few weeks, I would agree that new product development and focus on existing markets seems to be the key for growth in the next six months.
Our key US clients certainly seem to be backing this theory, we have a number of new exciting opportunities, with no sign of the market slowing down. In June alone, the Life Sciences team have registered 37% more roles compared to May!
However, two major clients of Lawrence Harvey Inc discussed with me only last week how excited they were about the opportunity in the Asia-Pacific region. Suggesting that the regulations were not as tight as say, the US.
Very interested to know your thoughts!
Key Findings The top three key priorities for H1 2016 (April-September 2016) as identified by respondents include new product development, improving operational efficiency, and expansion in current market Developed markets such as the US, the UK, and Japan are identified as important regions for growth over the next six months by pharmaceutical respondents New product development and IT infrastructure development will record a significant increase or notable increase in capital expenditure over the next six months Overall, 52% of executives operating in Europe assigned high preference for outright purchase of pharmaceutical equipment In Asia-Pacific, executives forecast packaging equipment and process equipment will offer significant revenue growth opportunities within the pharmaceutical industry